Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free SNSE Stock Alerts

Sensei Biotherapeutics (SNSE) Short Interest Ratio & Short Volume

Sensei Biotherapeutics logo
$20.32 -0.76 (-3.62%)
As of 02:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Sensei Biotherapeutics Short Interest Overview

As of April 30, 2026, Sensei Biotherapeutics (SNSE) had a short interest of 834,411 shares sold short, representing 81.01% of the public float. This marks a -2.50% decrease in short interest since the prior report. The short interest ratio (days to cover) is 27.1, meaning it would take 27.1 days of the average trading volume of 225,068 shares to cover all short positions.

Current Short Interest
834,411 shares
Previous Short Interest
855,820 shares
Change Vs. Previous Month
-2.50%
Dollar Volume Sold Short
$22.21 million
Short Interest Ratio
27.1 Days to Cover
Last Record Date
April 30, 2026
Outstanding Shares
1,340,000 shares
Short Percent of Float
81.01%
Today's Trading Volume
12,306 shares
Average Trading Volume
225,068 shares
Today's Volume Vs. Average
5%
Short Selling Sensei Biotherapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Sensei Biotherapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

SNSE Short Interest Over Time

SNSE Days to Cover Over Time

SNSE Percentage of Float Shorted Over Time

Sensei Biotherapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/2026834,411 shares $22.21 million -2.5%81.0%27.08 $26.62
4/15/2026855,820 shares $25.00 million -0.9%83.1%19.34 $29.21
3/31/2026863,539 shares $27.22 million +20.6%83.9%9.74 $31.52
3/13/2026715,845 shares $23.11 million +32.9%74.0%5.61 $32.28
2/27/2026538,588 shares $16.43 million +1,973.5%55.6%0.35 $30.50
2/13/202625,975 shares $236.11 thousand -0.4%2.7%0.61 $9.09
1/30/202626,068 shares $247.65 thousand -9.8%2.7%0.31 $9.50
1/15/202628,895 shares $335.47 thousand +11.4%3.0%0.25 $11.61
12/31/202525,945 shares $276.83 thousand -33.7%2.7%0.75 $10.67
12/15/202539,109 shares $308.57 thousand +4,114.3%4.0%0.21 $7.89
11/28/2025928 shares $7.91 thousand -82.6%0.1%0.03 $8.52
11/14/20255,342 shares $42.79 thousand -80.9%0.6%0.22 $8.01
10/31/202528,027 shares $257.01 thousand +86.3%2.9%0.24 $9.17
10/15/202515,000 shares $205.20 thousand +57.9%1.8%0.5 $13.68
9/30/20259,500 shares $89.78 thousand -8.7%1.2%0.6 $9.45
9/15/202510,400 shares $91.56 thousand +1.0%1.3%0.7 $8.80
8/31/202510,300 shares $83.20 thousand -21.4%1.2%0.6 $8.08
8/15/202513,100 shares $113.71 thousand +65.8%1.6%0.7 $8.68
7/31/20257,900 shares $59.09 thousand +9.7%1.0%0.5 $7.48
7/15/20257,200 shares $57.24 thousand -48.6%0.9%0.8 $7.95
6/30/202514,000 shares $120.12 thousand +211.1%1.7%1.4 $8.58
6/15/20254,500 shares $27.00 thousand -93.5%0.5%0 $6.00
5/31/202569,700 shares $21.40 thousand -64.7%0.4%0 $0.31
5/15/2025197,200 shares $68.63 thousand -50.5%1.2%0.1 $0.35
4/30/2025398,100 shares $160.43 thousand -24.0%2.4%0.2 $0.40
4/15/2025523,700 shares $239.85 thousand -72.6%3.2%0.2 $0.46
3/31/20251,910,000 shares $752.54 thousand +1,478.5%11.6%0.7 $0.39
3/15/2025121,000 shares $54.57 thousand -17.5%0.7%0.4 $0.45
2/28/2025146,700 shares $68.36 thousand -14.1%0.9%0.4 $0.47
2/15/2025170,700 shares $81.25 thousand -36.0%1.0%0.4 $0.48
1/31/2025266,500 shares $125.26 thousand -64.8%1.6%0.6 $0.47
1/15/2025757,800 shares $384.89 thousand +594.0%4.6%1.5 $0.51
12/31/2024109,200 shares $53.52 thousand +30.5%0.7%0.2 $0.49
12/15/202483,700 shares $36.83 thousand -63.1%0.5%0.2 $0.44
11/30/2024226,700 shares $122.64 thousand +13.2%1.4%0.5 $0.54
11/15/2024200,300 shares $90.84 thousand +2.9%1.2%0.5 $0.45
10/31/2024194,700 shares $92.44 thousand -12.8%1.2%0.6 $0.47
10/15/2024223,200 shares $103.79 thousand -12.4%1.4%0.9 $0.47
9/30/2024254,800 shares $152.37 thousand +1.7%1.5%4.9 $0.60
9/15/2024250,600 shares $135.32 thousand -5.2%1.5%5.4 $0.54
NNVC FDA = New Momentum Wave! (Ad)

NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measles at a time when no approved antiviral treatments exist and cases are resurging globally. Beyond measles, NV-387 is designed as a broad-spectrum platform targeting RSV, influenza, coronaviruses, Mpox, and more - giving NNVC exposure to multiple large markets as Phase II trials advance.tc pixel

See why this FDA milestone could be a catalyst for NNVC
8/31/2024264,400 shares $160.17 thousand -0.2%1.6%7.3 $0.61
8/15/2024265,000 shares $161.39 thousand -0.9%1.6%2.6 $0.61
7/31/2024267,500 shares $181.37 thousand -2.3%1.6%2 $0.68
7/15/2024273,900 shares $196.52 thousand -2.4%1.7%1.2 $0.72
6/30/2024280,600 shares $174.00 thousand -3.2%1.7%1.2 $0.62
6/15/2024289,900 shares $185.04 thousand +2.6%1.8%1.2 $0.64
5/31/2024282,600 shares $209.01 thousand +250.6%1.7%1.1 $0.74
5/15/202480,600 shares $120.09 thousand +34.1%0.5%0.4 $1.49
4/30/202460,100 shares $60.70 thousand -25.8%0.4%0.4 $1.01
4/15/202481,000 shares $81.41 thousand -48.1%0.5%1.2 $1.01
3/31/2024156,200 shares $164.01 thousand +7.1%1.0%2.5 $1.05
3/15/2024145,900 shares $147.36 thousand +4.1%0.9%2.4 $1.01
2/29/2024140,100 shares $119.09 thousand -2.1%0.9%2.5 $0.85
2/15/2024143,100 shares $112.35 thousand -11.4%0.9%2.8 $0.79
1/31/2024161,500 shares $132.43 thousand -6.5%1.0%2.7 $0.82
1/15/2024172,700 shares $132.98 thousand -14.1%1.1%2.4 $0.77
12/31/2023201,000 shares $139.09 thousand +2.3%1.2%2.9 $0.69
12/15/2023196,500 shares $129.69 thousand +31.4%1.2%3.1 $0.66
11/30/2023149,600 shares $107.71 thousand -11.4%0.9%2.8 $0.72
11/15/2023168,800 shares $102.09 thousand +25.6%1.0%3.6 $0.60
10/31/2023134,400 shares $95.56 thousand -1.9%0.8%3.1 $0.71
10/15/2023137,000 shares $101.38 thousand -0.2%0.8%6.9 $0.74
9/30/2023137,200 shares $109.76 thousand -14.4%0.8%7.7 $0.80
9/15/2023160,300 shares $132.10 thousand +10.4%0.9%7.8 $0.82
8/31/2023145,200 shares $145.20 thousand -5.8%0.8%6.9 $1.00
8/15/2023154,100 shares $166.43 thousand +3.6%0.9%7.1 $1.08
7/31/2023148,800 shares $187.49 thousand -2.2%0.8%6.6 $1.26
7/15/2023152,200 shares $196.34 thousand -8.7%0.9%2.2 $1.29
6/30/2023166,700 shares $190.04 thousand +11.9%0.9%2.3 $1.14
6/15/2023149,000 shares $199.66 thousand -0.9%0.8%2 $1.34
5/31/2023150,300 shares $219.44 thousand -2.9%0.7%2 $1.46
5/15/2023154,800 shares $224.46 thousand -15.5%1.0%2 $1.45
4/30/2023183,100 shares $272.82 thousand +72.4%1.1%2.3 $1.49
4/15/2023106,200 shares $159.30 thousand -3.5%0.7%1.3 $1.50
3/31/2023110,000 shares $165 thousand -1.9%0.7%3.3 $1.50
3/15/2023112,100 shares $155.82 thousand +46.9%0.7%2.9 $1.39
2/28/202376,300 shares $119.79 thousand -3.3%0.5%1.7 $1.57
2/15/202378,900 shares $112.83 thousand +24.6%0.5%1.7 $1.43
1/31/202363,300 shares $87.99 thousand +0.6%0.4%1.2 $1.39
1/15/202362,900 shares $98.75 thousand -23.2%0.4%1.2 $1.57
12/30/202281,900 shares $122.03 thousand -30.2%0.5%1.5 $1.49
12/15/2022117,300 shares $181.82 thousand -43.8%0.7%2.2 $1.55
11/30/2022208,800 shares $296.50 thousand +14.9%1.2%4.4 $1.42
11/15/2022181,700 shares $258.01 thousand -4.5%1.1%3.9 $1.42
10/31/2022190,200 shares $275.79 thousand -12.1%1.1%4.7 $1.45
10/15/2022216,300 shares $328.78 thousand +15.3%1.3%5.9 $1.52
9/30/2022187,600 shares $290.78 thousand -1.8%1.1%5 $1.55
9/15/2022191,000 shares $383.91 thousand -0.8%1.1%2.8 $2.01
8/31/2022192,600 shares $367.87 thousand -5.7%1.1%2.3 $1.91
8/15/2022204,200 shares $453.32 thousand -1.9%1.3%1.9 $2.22
NNVC FDA = New Momentum Wave! (Ad)

NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measles at a time when no approved antiviral treatments exist and cases are resurging globally. Beyond measles, NV-387 is designed as a broad-spectrum platform targeting RSV, influenza, coronaviruses, Mpox, and more - giving NNVC exposure to multiple large markets as Phase II trials advance.tc pixel

See why this FDA milestone could be a catalyst for NNVC
7/31/2022208,200 shares $397.66 thousand -4.7%1.3%1.7 $1.91
7/15/2022218,500 shares $450.11 thousand -11.2%1.4%1.7 $2.06
6/30/2022246,100 shares $558.65 thousand -68.6%1.6%1.8 $2.27
6/15/2022783,300 shares $1.50 million +10.5%5.0%5.6 $1.91
5/31/2022708,800 shares $1.35 million -3.1%4.5%6.9 $1.90
5/15/2022731,700 shares $1.09 million +11.1%4.7%8.6 $1.49
4/30/2022658,600 shares $1.02 million +17.9%4.2%8.9 $1.55
4/15/2022558,700 shares $1.07 million -0.6%3.6%7.8 $1.92
3/31/2022562,100 shares $1.30 million +20.2%3.6%7.8 $2.31
3/15/2022467,800 shares $1.14 million +7.4%3.0%5.6 $2.43
2/28/2022435,700 shares $1.57 million +6.7%2.8%4.9 $3.61
2/15/2022408,500 shares $1.76 million +10.6%2.5%4.6 $4.30
1/31/2022369,300 shares $1.78 million +15.1%2.3%4.2 $4.82
1/15/2022320,900 shares $1.68 million -4.1%1.9%3.8 $5.24
12/31/2021334,700 shares $1.94 million +2.3%N/A0 $5.80
12/15/2021327,300 shares $1.70 million -6.1%2.0%3.9 $5.20
11/30/2021348,400 shares $2.40 million -8.3%2.1%3.4 $6.88
11/15/2021380,100 shares $3.75 million -14.8%2.3%3.4 $9.87
10/29/2021446,000 shares $3.88 million -1.4%2.7%3.5 $8.69
10/15/2021452,400 shares $3.45 million -14.0%2.7%3.6 $7.63
9/30/2021525,900 shares $5.53 million +121.1%3.1%4.3 $10.52
9/15/2021237,900 shares $2.55 million -15.8%1.4%1.8 $10.70
8/31/2021282,500 shares $3.05 million -14.7%1.7%2.7 $10.78
8/13/2021331,200 shares $2.63 million No Change2.0%3.6 $7.95

SNSE Short Interest - Frequently Asked Questions

Short interest is the volume of Sensei Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 834,411 shares of SNSE short. 81.01% of Sensei Biotherapeutics' shares are currently sold short. Learn More on Sensei Biotherapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SNSE shares currently have a short interest ratio of 27.1. Learn More on Sensei Biotherapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 81.01% of Sensei Biotherapeutics' floating shares are currently sold short.

Sensei Biotherapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 834,411 shares, a drop of 2.5% from the previous total of 855,820 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

81.01% of Sensei Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sensei Biotherapeutics: Edesa Biotech, Inc. (7.64%), Connect Biopharma Holdings Limited Sponsored ADR (2.59%), Journey Medical Corporation (15.82%), Assertio Holdings, Inc. (4.76%), TuHURA Biosciences, Inc. (13.00%), Innate Pharma S.A. Sponsored ADR (0.14%), Equillium, Inc. (5.41%), Alpha Cognition Inc. (0.96%), vTv Therapeutics Inc. (3.70%), Genelux Corporation (7.59%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($86.09 billion), Invesco QQQ ($39.89 billion), iShares Russell 2000 ETF ($26.13 billion), Western Digital Corporation ($12.66 billion), Salesforce Inc. ($12.29 billion), Sandisk Corporation ($11.87 billion), SPDR S&P Biotech ETF ($9.82 billion), Lumentum Holdings Inc. ($8.51 billion), iShares 20+ Year Treasury Bond ETF ($7.76 billion), and Bloom Energy Corporation ($7.40 billion). View all of the most shorted stocks.

Short selling SNSE is an investing strategy that aims to generate trading profit from Sensei Biotherapeutics as its price is falling. SNSE shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Sensei Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SNSE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNSE, twice per month. The most recent reporting period available is April, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like SNSE:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:SNSE) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...
Equiscreen | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Is this AI lab Elon’s SpaceX lifeline?
Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...
Chaikin Analytics | Sponsoredtc pixel